|Bid||300.91 x 1800|
|Ask||303.62 x 900|
|Day's Range||299.65 - 304.83|
|52 Week Range||281.42 - 531.80|
|Beta (5Y Monthly)||1.28|
|PE Ratio (TTM)||45.20|
|Earnings Date||Oct 31, 2022 - Nov 04, 2022|
|Forward Dividend & Yield||1.28 (0.41%)|
|Ex-Dividend Date||Aug 12, 2022|
|1y Target Est||473.45|
Subscribe to Yahoo Finance Plus to view Fair Value for TECH
These are the healthcare stocks with the best value, fastest growth, and most momentum for October 2022.
Bio-Techne Corporation (NASDAQ: TECH) today announced the expansion of the Advanced Cell Diagnostics (ACD)-branded RNAscope™ in situ hybridization (ISH) portfolio with the release of new automated co-detection assays specifically designed for the Roche DISCOVERY ULTRA Platform, enabling simultaneous detection of RNA and protein on the same tissue section.
Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, today announced that it has taken legal action in the United Kingdom to halt the infringement of its patented RNAscope® ISH technology by Molecular Instruments, Inc.